注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
bluebird bio Inc是一家生物技术公司。该公司主要致力于研究、开发和商业化基因治疗遗传疾病。该公司在基因疾病方面的基因治疗计划包括以下几项。包括B-地中海贫血计划,作为镰状细胞病(SCD)治疗的扁豆球蛋白产品候选物以及作为cerebral adrenoleukodystrophy(CALD)治疗剂的elivaldogene autotemcel(eli-cel)。它使用慢病毒载体(LVV)平台,定制设计每种治疗方案,以解决疾病的根本原因。该公司正在开发lovotibeglogene autotemcel(lovo-cel)。作为SCD患者的一次性治疗,SCD是一种由B-thalassemia的单一突变引起的遗传疾病,导致abnormal sickle hemoglobin(HbS)的产生。B-thalassemia(beti-cel)的BLA用于接受red blood cell(RBC)输注的患者的B-thalassemia。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Mitchell H. Finer | 64 | 2010 | Member of Scientific Advisory Board |
Najoh Tita-Reid | - | 2021 | Director |
Nick Leschly | 50 | 2010 | Director |
Andrew M. Scharenberg | - | - | Member of Scientific Advisory Board |
Philip R. Reilly | 75 | 2010 | Member of Scientific Advisory Board |
Malcolm K. Brenner | 71 | 2011 | Member of Scientific Advisory Board |
Christof von Kalle | - | 2011 | Member of Scientific Advisory Board |
R. Keith Humphries | - | 2011 | Member of Scientific Advisory Board |
Mark L. Vachon | 64 | 2014 | Independent Chairman |
Stephen P. Goff | 71 | 2011 | Member of Scientific Advisory Board |
Philippe Leboulch | - | - | Co-Chair of Scientific Advisory Board |
John O. Agwunobi | 58 | 2017 | Independent Director |
Andrew Obenshain | 48 | 2016 | President, CEO & Director |
Richard A. Paulson | 56 | 2023 | Independent Director |
Elisabeth Leiderman | 46 | 2021 | Independent Director |
Charlotte Jones-Burton | 49 | 2022 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核